Positive News SentimentPositive NewsNASDAQ:ATAI Atai Life Sciences (ATAI) Stock Price, News & Analysis → Crypto Pioneer Says: “The last crypto bull market has begun.” (From InvestorPlace) (Ad) Free ATAI Stock Alerts $1.91 -0.03 (-1.55%) (As of 05/14/2024 ET) Add Compare Share Share Today's Range$1.90▼$2.0050-Day Range$1.63▼$2.6052-Week Range$1.03▼$2.85Volume397,886 shsAverage Volume1.57 million shsMarket Capitalization$319.75 millionP/E RatioN/ADividend YieldN/APrice Target$10.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Atai Life Sciences alerts: Email Address Atai Life Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside449.7% Upside$10.50 Price TargetShort InterestBearish5.43% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.89Based on 2 Articles This WeekInsider TradingSelling Shares$164,742 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($0.80) to ($0.77) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.2.28 out of 5 starsMedical Sector1794th out of 2,771 stocksPharmaceutical Preparations Industry842nd out of 1,288 stocks 3.5 Analyst's Opinion Consensus RatingAtai Life Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAtai Life Sciences has only been the subject of 3 research reports in the past 90 days.Read more about Atai Life Sciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted5.43% of the float of Atai Life Sciences has been sold short.Short Interest Ratio / Days to CoverAtai Life Sciences has a short interest ratio ("days to cover") of 4.Change versus previous monthShort interest in Atai Life Sciences has recently increased by 6.95%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldAtai Life Sciences does not currently pay a dividend.Dividend GrowthAtai Life Sciences does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ATAI. Previous Next 3.3 News and Social Media Coverage News SentimentAtai Life Sciences has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.57 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Atai Life Sciences this week, compared to 1 article on an average week.Search InterestOnly 12 people have searched for ATAI on MarketBeat in the last 30 days. This is a decrease of -52% compared to the previous 30 days.MarketBeat FollowsOnly 5 people have added Atai Life Sciences to their MarketBeat watchlist in the last 30 days. This is a decrease of -74% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Atai Life Sciences insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $164,742.00 in company stock.Percentage Held by Insiders31.20% of the stock of Atai Life Sciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 28.41% of the stock of Atai Life Sciences is held by institutions.Read more about Atai Life Sciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Atai Life Sciences are expected to grow in the coming year, from ($0.80) to ($0.77) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Atai Life Sciences is -6.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Atai Life Sciences is -6.59, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAtai Life Sciences has a P/B Ratio of 1.30. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Atai Life Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Unstoppable ProsperityCharles Payne Demystifies OptionsWhen it comes to retirement, everyone fears one thing… Outliving their retirement savings. You'll discover conservative, beginner-friendly options strategies which could help to cash flow your stock portfolio. Click here to register for free. About Atai Life Sciences Stock (NASDAQ:ATAI)Atai Life Sciences N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. ATAI Life Sciences N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.Read More ATAI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ATAI Stock News HeadlinesMay 2, 2024 | forbes.comHow AI Could Transform Drug Development And The Life SciencesMay 1, 2024 | finance.yahoo.comOpioid Withdrawal Syndrome Drug Market to Surge at a CAGR of 4.0% by 2034 | DelveInsightApril 30, 2024 | forbes.comAI Is Moving Biology From Science To Engineering, Advancing MedicineApril 24, 2024 | proactiveinvestors.comatai Life Sciences investee Beckey Psytech starts dosing patients in second part of treatment-resistant depression studyApril 24, 2024 | finance.yahoo.comatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant DepressionApril 24, 2024 | globenewswire.comatai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech's Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant DepressionApril 18, 2024 | stockhouse.comatai Life Sciences Announces the Publication of Beckley Psytech's Phase 1 Study of BPL-003 in the Journal of PsychopharmacologyApril 18, 2024 | investing.comatai Life Sciences reports positive Phase 1 results for BPL-003April 17, 2024 | finance.yahoo.comatai Life Sciences Announces the Publication of Beckley Psytech’s Phase 1 Study of BPL-003 in the Journal of PsychopharmacologyApril 17, 2024 | proactiveinvestors.comatai announces publication of Beckley Psytech's Phase 1 study for novel 5-MeO-DMT assetApril 17, 2024 | msn.comAtai Life Sciences N.V. (ATAI) Price Target Decreased by 15.35% to 10.90April 15, 2024 | proactiveinvestors.comatai Life Sciences CEO Florian Brand spotlights psychedelic therapy milestones and upcoming catalystsApril 6, 2024 | investing.comAtai Life Sciences executive sells $114k in company stockApril 4, 2024 | msn.comAre You Looking for a Top Momentum Pick? Why atai Life Sciences N.V. (ATAI) is a Great ChoiceApril 3, 2024 | msn.comAtai Life Sciences upgraded at Maxim on Beckley investmentApril 2, 2024 | msn.comUT Tyler University Academy senior directs first student-led theater productionApril 1, 2024 | msn.comCould We Ever Have Sci-Fi Tech Like the ‘Star Trek’ Transporter? A New Roddenberry Entertainment Podcast Finds OutApril 1, 2024 | finance.yahoo.comAtai Life Sciences Full Year 2023 Earnings: EPS Beats Expectations, Revenues LagMarch 29, 2024 | msn.comAtai Life Sciences Q4 And Full-Year 2023 Results: Steep Cash Drain Yet 2026 Target Remains, Update On Psychedelic PipelineMarch 28, 2024 | msn.comIntranasal 5-MeO-DMT Clinical Trial Offers Hope For Treatment-Resistant DepressionMarch 28, 2024 | benzinga.comRecap: ATAI Life Sciences Q4 EarningsMarch 28, 2024 | proactiveinvestors.comatai Life Sciences funded into 2026; sets sights on key milestones for its psychedelic therapiesMarch 28, 2024 | msn.comATAI Life Sciences GAAP EPS of -$0.12 beats by $0.04March 28, 2024 | globenewswire.comatai Life Sciences Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate and Clinical HighlightsMarch 27, 2024 | proactiveinvestors.comatai-backed Beckley Psytech unveils positive results from DMT for treatment-resistant depression studySee More Headlines Receive ATAI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Atai Life Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/28/2024Today5/14/2024Next Earnings (Estimated)5/16/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ATAI CUSIPN/A CIK1420529 Webwww.atai.net.cn Phone49-89-2153-9035FaxN/AEmployees83Year FoundedN/APrice Target and Rating Average Stock Price Target$10.50 High Stock Price Target$15.00 Low Stock Price Target$6.00 Potential Upside/Downside+449.7%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.29) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-40,220,000.00 Net Margins-12,810.51% Pretax Margin-12,511.46% Return on Equity-45.08% Return on Assets-38.46% Debt Debt-to-Equity Ratio0.08 Current Ratio9.22 Quick Ratio9.22 Sales & Book Value Annual Sales$310,000.00 Price / Sales1,031.46 Cash FlowN/A Price / Cash FlowN/A Book Value$1.47 per share Price / Book1.30Miscellaneous Outstanding Shares167,410,000Free Float115,180,000Market Cap$319.75 million OptionableOptionable Beta0.92 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesMr. Christian Angermayer (Age 46)Founder & Chairman of the Supervisory Board Comp: $70kMr. Florian Brand (Age 37)Co-Founder, MD & CEO Comp: $835.44kDr. Srinivas G. Rao M.D. (Age 55)Ph.D., Co-Founder & Chief Scientific Officer Comp: $834.15kMs. Anne Johnson (Age 55)Chief Financial Officer Dr. Michael Raven Ph.D.Senior Vice President of OperationsMr. Frank Stegert (Age 43)Vice President of Investment & Venture Management Mr. Ryan Barrett (Age 43)Senior VP, General Counsel & Corporate Secretary Dr. Glenn Short Ph.D.Senior Vice President of Early DevelopmentDr. Sahil V. Kirpekar M.D. (Age 38)Chief Business Officer Dr. Kevin Craig M.D.Senior Vice President of Clinical DevelopmentMore ExecutivesKey CompetitorsPrecigenNASDAQ:PGENSilverback TherapeuticsNASDAQ:SBTXNkartaNASDAQ:NKTXAtea PharmaceuticalsNASDAQ:AVIRNature's Sunshine ProductsNASDAQ:NATRView All CompetitorsInsiders & InstitutionsChina Universal Asset Management Co. Ltd.Bought 12,693 shares on 4/29/2024Ownership: 0.019%Quattro Financial Advisors LLCBought 70,976 shares on 4/18/2024Ownership: 0.043%CRA Financial Services LLCBought 12,903 shares on 4/17/2024Ownership: 0.008%Kingswood Wealth Advisors LLCBought 30,000 shares on 4/15/2024Ownership: 0.018%Srinivas RaoSold 61,640 sharesTotal: $114,034.00 ($1.85/share)View All Insider TransactionsView All Institutional Transactions ATAI Stock Analysis - Frequently Asked Questions Should I buy or sell Atai Life Sciences stock right now? 3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Atai Life Sciences in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ATAI shares. View ATAI analyst ratings or view top-rated stocks. What is Atai Life Sciences' stock price target for 2024? 3 analysts have issued 12 month target prices for Atai Life Sciences' shares. Their ATAI share price targets range from $6.00 to $15.00. On average, they predict the company's stock price to reach $10.50 in the next year. This suggests a possible upside of 449.7% from the stock's current price. View analysts price targets for ATAI or view top-rated stocks among Wall Street analysts. How have ATAI shares performed in 2024? Atai Life Sciences' stock was trading at $1.41 at the start of the year. Since then, ATAI shares have increased by 35.5% and is now trading at $1.91. View the best growth stocks for 2024 here. When is Atai Life Sciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 16th 2024. View our ATAI earnings forecast. How were Atai Life Sciences' earnings last quarter? Atai Life Sciences (NASDAQ:ATAI) issued its earnings results on Thursday, March, 28th. The company reported ($0.12) EPS for the quarter, topping analysts' consensus estimates of ($0.17) by $0.05. The company earned $0.02 million during the quarter, compared to analysts' expectations of $0.90 million. Atai Life Sciences had a negative trailing twelve-month return on equity of 45.08% and a negative net margin of 12,810.51%. What ETF holds Atai Life Sciences' stock? AdvisorShares Psychedelics ETF holds 200,207 shares of ATAI stock, representing 5.43% of its portfolio. What other stocks do shareholders of Atai Life Sciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Atai Life Sciences investors own include Alphabet (GOOG), Baidu (BIDU), Costco Wholesale (COST), MannKind (MNKD), NVIDIA (NVDA), Schlumberger (SLB), Twitter (TWTR), Adobe (ADBE), Allergan (AGN) and Achaogen (AKAO). When did Atai Life Sciences IPO? Atai Life Sciences (ATAI) raised $200 million in an IPO on Friday, June 18th 2021. The company issued 14,300,000 shares at a price of $13.00-$15.00 per share. Credit Suisse, Citigroup, Cowen and Berenberg acted as the underwriters for the IPO and Cantor, RBC Capital Markets and Canaccord Genuity were co-managers. Who are Atai Life Sciences' major shareholders? Atai Life Sciences' stock is owned by many different retail and institutional investors. Top institutional investors include Quattro Financial Advisors LLC (0.04%), China Universal Asset Management Co. Ltd. (0.02%), Kingswood Wealth Advisors LLC (0.02%), CRA Financial Services LLC (0.01%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Anne Nagengast Johnson, Apeiron Investment Group Ltd, Christian Angermayer, Florian Brand, Gregory L Weaver and Srinivas Rao. View institutional ownership trends. How do I buy shares of Atai Life Sciences? Shares of ATAI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ATAI) was last updated on 5/14/2024 by MarketBeat.com Staff From Our PartnersDid Intel Just Dethrone Nvidia?Chaikin AnalyticsClaim Your Complimentary Bitcoin RewardCrypto Swap ProfitsCharles Payne Demystifies OptionsUnstoppable ProsperityRevolutionizing the Green Energy Space and Building Shareholder Value Along the WaySmall Cap SniperTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThe only AI company you should be looking atBehind the MarketsElon to Transform U.S. Economy? Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Atai Life Sciences Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.